Advertisement

Dermatologic Manifestations in Renal Failure

  • Lídice Dufrechou Varela
  • Alejandra Larre Borges
  • Andrea Nicola Centanni
Chapter

Abstract

Chronic renal failure (CRF) is a major public health problem worldwide. Patients living with CRF are considered to follow a chronic inflammatory state due to multiple factors. From a dermatologic point of view, there is a high frequency of dermatoses associated with this condition. They can be divided into specific and nonspecific, the latter having the highest prevalence, but all of them show a significant impact on the quality of life of affected patients. Xerosis, bruising, and itching are ubiquitous in this population and are considered multifactorial. Among them, xerosis, pale skin and itching are the most prevalent ones. On the other hand, specific dermatoses are classified as acquired perforating disorders, bullous dermatoses, calcification disorders, nephrogenic systemic fibrosis, specific nail changes, and uremic frost. Most skin disorders are benign and do not affect the course of CRF. On several occasions skin disorders can predict the initiation of a renal replacement plan, or may be precipitated by it.

Keywords

Chronic renal failure Hemodialysis Nonspecific dermatoses Specific dermatoses 

Notes

Glossary

Dyschromia 

Alteration of the color of the skin.

Gynecomastia 

Enlargement of the breast in the males, caused by an excess of estrogens.

Macroglossia 

Excessively large tongue.

Microangiopathy 

Pathologic processes of the microvessels.

Pruritogenic substances 

Substances capable of causing pruritus (itching).

Raynaud’s phenomenon 

Abrupt onset of digital paleness followed by cyanosis and erythema in response to cold.

Teratogenic effect 

Capacity of some substances of generate physical defects in the developing embryo.

Uroporphyrins 

Porphyrins produced by oxidation of uroporphyrinogen, which can be excreted in excess in the urine in the context of porphyrias.

Xerostomia 

Decreased salivary flow (dry mouth).

References

  1. 1.
    Registro Uruguayo de Diálisis. www.nefrouruguay.com.
  2. 2.
    Barco D, Giménez-Arnau A. Xerosis: a dysfunction of the epidermal barrier. Actas Dermosifilogr. 2008;99:671–82.CrossRefGoogle Scholar
  3. 3.
    Lupi O, Rezende L, Zangrando M, Sessim M, Silveira CB, Sepulcri MAS, et al. Manifestacões cutáneas na doenca renal terminal. An Bras Dermatol. 2011;86(2):319–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Falodun O, Ogunbiyi A, Salako B, George AK. Skin changes in patients with chronic renal failure. Saudi J Kidney Dis Transpl [serial online]. 2011. Cited 16 Mar 2015.;22:268–72.Google Scholar
  5. 5.
    Udayakumar P, Balasubramanian S, Ramalingam KS, Lakshmi C, Srinivas CR, Mathew AC. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Indian J Dermatol Venereol Leprol. 2006;72(2):119–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Leena JA, Noman MU, Islam MMSU, Ahmed AS, Ahmed DS, Rahma MM. Cutaneous manifestations of chronic kidney disease – an observational study in 100 cases. Faridpur Med Coll J. 2012;7:33–6.CrossRefGoogle Scholar
  7. 7.
    Brewster UC. Dermatologic disease in patients with CKD. Am J Kidney Dis. 2008;51(2):331–44.CrossRefPubMedGoogle Scholar
  8. 8.
    Kidney International Supplements. 2013;3:136–50. doi: https://doi.org/10.1038/kisup.2012.72.
  9. 9.
    Kuypers D. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5(3):157–70.PubMedGoogle Scholar
  10. 10.
    Thomas EA, Pawar B, Thomas A. A prospective study of cutaneous abnormalities in patients with chronic kidney disease. Indian J Nephrol. 2012;22:116–20.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Batista Peres LA, Passarini SR, Ferreira de Barros Tocollini Branco M, Kruger LA. Skin lesions in chronic renal dialysis. J Bras Nefrol. 2014;36(1):1–6.CrossRefGoogle Scholar
  12. 12.
    Attia EAS, Hassan SI, Youseef NM. Cutaneous disorders in uremic patients on hemodialysis: an Egyptian case-controlled study. Inter J Dermatol. 2010;49:1024–30.CrossRefGoogle Scholar
  13. 13.
    Robinson-Bostom L, DiGiovanna JJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol. 2000;43(6):987–90.CrossRefGoogle Scholar
  14. 14.
    Cordova KB, Oberg TJ, Malik M, Robinson-Bostom L. Dermatologic conditions seen in end-stage renal disease. Semin Dial. 2009;22(1):45–55.CrossRefPubMedGoogle Scholar
  15. 15.
    Avermaete A, Altmeyer P, Bacharach-Buhles M. Skin changes in dyalisis patients: a review. Nephrol Dial Transplant. 2001;16:2293–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Fett N, Haynes A, Joy Propert KJ, Margolis DJ. Predictors of malignancy development in patients with chronic pruritus. J Dermatol Sci. 2016;82(2):123–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang A, Elshehadeh R, Rao D, Yap E. Roles of aldosterone receptor antagonists in heart failures, hypertension, and chronic kidney disease. J Nurse Pract. 2016;12(3):201–6.CrossRefGoogle Scholar
  18. 18.
    Chao CT, Lai CF, Huang JW. Risk factors for herpes zoster reactivation in maintenance hemodialysis patients. Eur J Intern Med. 2012;23:711–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Mazen S, Kurban AB, Kibbi A-G. Cutaneous manifestations of chronic kidney disease. Clin Dermatol. 2008;26:255–64.CrossRefGoogle Scholar
  20. 20.
    Belloni Fortina A, Piaserico S, Alaibac M. 2009. Squamous cell carcinoma. In: The SCOPE Collaborative Group, editor. Skin cancer after organ transplantation. Cancer treatment and research 146. Rosen T, Series Editor. Springer, p. 241–61.Google Scholar
  21. 21.
    Chaturvedy M. Dermatologic problems in CKD; ocular manifestations in CKD. Clin Nephrol. 2012;1(4):284–90.Google Scholar
  22. 22.
    Charkhchian M, Beheshti A, Zangivand AA. Nail disorder among patients on maintenance hemodialysis. Dermatol Sin. 2003;31(1):7–10.CrossRefGoogle Scholar
  23. 23.
    Saray Y, Seckin D, Gulec AT, Akgun S. Nail disorders in hemodialysis patients and transplant recipients: a case-control study. J Am Acad Dermatol. 2004;50(2):197–202.CrossRefPubMedGoogle Scholar
  24. 24.
    Green JJ, Manders SM. Pseudoporphyria. J Am Acad Dermatol. 2001;44(1):100–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Daudén Tello E, Ruiz Genao D, Fraga FJ. Calcificación vascular cutánea. Correlación clínicopatológica y proposición de una nueva clasificación de las calcinosis. Actas Dermosifiliogr. 2002;93(1):23–34.Google Scholar
  26. 26.
    Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012;26(4):489–503.CrossRefPubMedGoogle Scholar
  27. 27.
    Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Jimenez SA, Arlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, et al. Dialysis-associated systemic fibrosis. Study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum. 2004;50:2660–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Shavit L, Grenader T, Lifschitz M, Slotki I. Use of pregabalin in the management of chronic uremic pruritus. J Pain Symptom Manage. 2013;45(4):776–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69:1626–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis. 2015;65(5):763–72.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ramsey HM, Fryer AA, Reece S, Smith AG, Harden PN. Clinical risk factors associated with nonmelanoma skin cáncer in renal transplant recipients. Am J Kidney Dis. 2000;36(1):167–76.CrossRefGoogle Scholar
  33. 33.
    Athar M, Walsh SB, Kopelvich L, Elmets CA. Pathogenesis of nonmelanoma skin cancers in organ transplant recipients. Arch Biochem Biophys. 2011;508(2):159–63.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Keczkes K, Farr M. Bullous dermatosis of chronic renal failure. Br J Dermatol. 1976;95(5):541–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care. 2008;35(2):251–vi.CrossRefGoogle Scholar
  36. 36.
    Mohan D, Railey M. Uremic frost. Kidney Int. 2012;81:1153.CrossRefPubMedGoogle Scholar
  37. 37.
    Szepietowski JC, Reich A, Schwatrz RA. Uraemic xerosis. Nephrol Dial Transplant. 2004;19(11):2709–12.CrossRefPubMedGoogle Scholar
  38. 38.
    Winhoven S. Nodular prurigo – a retrospective analysis. Br J Dermatol. 1985;113:431–9.CrossRefGoogle Scholar
  39. 39.
    Carrascosa JM, Ferrándiz C. Estrategias terapéuticas en el prurigo nodular. Piel. 2001;16(7):360–4.CrossRefGoogle Scholar
  40. 40.
    Glynne P, Deacon A, Goldsmith D, Pusey C, Clutterbuck E. Bullous dermatoses in end-stage renal failure: porphyria or pseudoporphyria? Am J Kidney Dis. 1999;34(1):155–60.CrossRefPubMedGoogle Scholar
  41. 41.
    Zettersten EM, Ghadially R, Feingold KR, Crumrine D, Elias PM. Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J Am Acad Dermatol. 1997;37(3 Pt 1):403–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Weisshaar E, Dunker N, Gollnick H. Capsaicin therapy in humans with hemodialysis-related pruritus. Neurosci Lett. 2003;345(3):192–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Molinar VE, Taylor SC, Pandya AG. What’s new in objective assessment and treatment facial hyperpigmentation? Dermatol Clin. 2014;32:123–35.CrossRefPubMedGoogle Scholar
  44. 44.
    Sarkar R, Arora P, Grag KV. Cosmeceuticals for hyperpigmentation: what is available? J Cutan Aesthet Surg. 2013;6(1):4–11.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Arora P, Sarkar R, Grag VK, Arya L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5(2):93–103.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Omi T, Yamashita R, Kawana S, Sato S, Naito Z. Low fluence Q-switched Nd: YAG laser toning and Q-switched ruby laser in the treatment of melasma: a comparative split-face ultrastructural study. Laser Ther. 2012;21(1):15–21.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Guerrero D. Dermocosmetic management of hyperpigmentations. Ann Dermatol Venereol. 2012;139(Suppl 3:S1):S115–8.CrossRefPubMedGoogle Scholar
  48. 48.
    González-Lara L, Gómez-Bernal S, Vázquez-López F, VivancoAllende B. Acquired perforating dermatosis: a report of 8 cases. Actas Dermosifilogr. 2014;105(6):e-39–43.CrossRefGoogle Scholar
  49. 49.
    Farrell A. Acquired perforating dermatosis in renal and diabetic patients. 1997;9056(349):895–96.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  • Lídice Dufrechou Varela
    • 1
  • Alejandra Larre Borges
    • 2
  • Andrea Nicola Centanni
    • 3
  1. 1.Assistant Professor of DermatologyHospital de Clínicas “Dr. Manuel Quintela”de MontevideoUruguay
  2. 2.Adjunct Professor of DermatologyHospital de Clìnicas “Dr. Manuel Quintela”de MontevideoUruguay
  3. 3.Hospital de Clínicas “Dr. Manuel Quintela”MontevideoUruguay

Personalised recommendations